Sen Xie,Ligong Tang,Xiong Cai,Zhixiong Li,Huanhuan Chen,Hui Bao. Might liver transplantation recipients with primary hepatocellular carcinoma benefit from GVT effect of aGVHD?. Oncol Transl Med, 2014, 13: 535-538.
Might liver transplantation recipients with primary hepatocellular carcinoma benefit from GVT effect of aGVHD?
Received:June 30, 2014  Revised:November 03, 2014
View Full Text  View/Add Comment  Download reader
KeyWord:hepatocellular carcinoma (HCC); liver transplantation; acute graft versus host disease; graft versus tumor
Author NameAffiliationE-mail
Sen Xie Department of Organ Transplantation,Wuhan General Hospital of Guangzhou Military Command, Wuhan 430070, China dr.xiesen@medmail.com.cn 
Ligong Tang Department of Organ Transplantation,Wuhan General Hospital of Guangzhou Military Command, Wuhan 430070, China  
Xiong Cai Department of Organ Transplantation,Wuhan General Hospital of Guangzhou Military Command, Wuhan 430070, China  
Zhixiong Li Department of Organ Transplantation,Wuhan General Hospital of Guangzhou Military Command, Wuhan 430070, China  
Huanhuan Chen Department of Organ Transplantation,Wuhan General Hospital of Guangzhou Military Command, Wuhan 430070, China  
Hui Bao Department of Organ Transplantation,Wuhan General Hospital of Guangzhou Military Command, Wuhan 430070, China  
Hits: 8299
Download times: 8722
Abstract:
      Objective: We aimed to access if acute graft-versus-host disease (aGVHD) in liver transplantation recipients of hepatocellular carcinoma (HCC) might develop a graft-versus-tumor effect (GVT) other than immunological damage which would benefit prophylaxis of tumor recurrence. Methods: Dynamic observation of 3 cases of liver transplantation recipients of HCC and cirrhosis, which developed manifestations of fever, skin rash, watery diarrhea, pancytopenia and were finally diagnosed as aGVHD. Two of which got recovered from intravenously pulse methylprednisolone, high-dose intravenous immunoglobulin, antibiotics administration simultaneously and promptly withdrawal of oral immunosuppressants. Two survivors were follow-up regularly with biological monitoring and imaging surveillance for tumor recurrence thereafter. Results: Two recipients survived healthily with stable liver graft function and normal serum AFP level and blood routine test. No sign of tumor recurrence was found in repeat imaging examinations for liver graft, lung, brain and other tissue or organs within a period of 96 months and 17 months to date, respectively. Conclusion: Despite of the fatal damage to according organs and tissue, it suggest that aGVHD in liver recipients of HCC may also develop a GVT effect and benefit prophylaxis of tumor recurrence and result in a long-term healthy recipients survival.
Close